Subscribe To
Ocular therapeutix™ announces fda approval of supplemental new drug application (snda) for dextenza® (dexamethasone ophthalmic insert) 0.4 mg for intracanalicular use for the treatment of ocular itchi
BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, deve...
October 11, 2021, 12:30 pm
Ocular therapeutix™ announces fda approval of supplemental new drug application (snda) for dextenza® (dexamethasone ophthalmic insert) 0.4 mg for intracanalicular use for the treatment of ocular itchi
BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, deve...
October 11, 2021, 12:30 pm
Ocular therapeutix™ announces fda approval of supplemental new drug application (snda) for dextenza® (dexamethasone ophthalmic insert) 0.4 mg for intracanalicular use for the treatment of ocular itchi
BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, deve...
October 11, 2021, 12:30 pm
Ocular therapeutix™ announces fda approval of supplemental new drug application (snda) for dextenza® (dexamethasone ophthalmic insert) 0.4 mg for intracanalicular use for the treatment of ocular itchi
BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, deve...
October 11, 2021, 12:30 pm
I-80 gold outlines details of financing package for nevada acquisitions
i-80 Gold Corp. said it will ask shareholders to approve the issue of common shares and other securitie...
October 11, 2021, 8:38 am
I-80 gold outlines details of financing package for nevada acquisitions
i-80 Gold Corp. said it will ask shareholders to approve the issue of common shares and other securitie...
October 11, 2021, 8:38 am
I-80 gold outlines details of financing package for nevada acquisitions
i-80 Gold Corp. said it will ask shareholders to approve the issue of common shares and other securitie...
October 11, 2021, 8:38 am
Davita climate action goals approved by the science based target initiative
DENVER, Oct. 11, 2021 /PRNewswire/ -- DaVita furthers commitment to climate action goals with validation from the Science Based Targets initiative (S...
October 11, 2021, 6:02 am
Davita climate action goals approved by the science based target initiative
DENVER, Oct. 11, 2021 /PRNewswire/ -- DaVita furthers commitment to climate action goals with validation from the Science Based Targets initiative (S...
October 11, 2021, 6:02 am
Davita climate action goals approved by the science based target initiative
DENVER, Oct. 11, 2021 /PRNewswire/ -- DaVita furthers commitment to climate action goals with validation from the Science Based Targets initiative (S...
October 11, 2021, 6:02 am
Beigene announces brukinsa® (zanubrutinib) approved for treatment of patients with mantle cell lymphoma in australia
CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE #BTKi--BeiGene Announces BRUKINSA® (Zanubrutinib) appro...
October 10, 2021, 5:00 pm
Beigene announces brukinsa® (zanubrutinib) approved for treatment of patients with mantle cell lymphoma
SYDNEY & CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE #BTKi--BeiGene Announces BRUKINSA® (Zanubrutinib)...
October 10, 2021, 5:00 pm
Beigene announces brukinsa® (zanubrutinib) approved for treatment of patients with mantle cell lymphoma in australia
CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE #BTKi--BeiGene Announces BRUKINSA® (Zanubrutinib) appro...
October 10, 2021, 5:00 pm
Beigene announces brukinsa® (zanubrutinib) approved for treatment of patients with mantle cell lymphoma
SYDNEY & CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE #BTKi--BeiGene Announces BRUKINSA® (Zanubrutinib)...
October 10, 2021, 5:00 pm
Beigene announces brukinsa® (zanubrutinib) approved for treatment of patients with mantle cell lymphoma in australia
CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE #BTKi--BeiGene Announces BRUKINSA® (Zanubrutinib) appro...
October 10, 2021, 5:00 pm
Beigene announces brukinsa® (zanubrutinib) approved for treatment of patients with mantle cell lymphoma
SYDNEY & CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE #BTKi--BeiGene Announces BRUKINSA® (Zanubrutinib)...
October 10, 2021, 5:00 pm
Enzyvant receives fda approval for rethymic® (allogeneic processed thymus tissue-agdc), a one-time regenerative tissue-based therapy for pediatric congenital athymia
RETHYMIC is the first and only FDA-approved treatment indicated for immune reconstitution in pediatric patients with congenital athymia...
October 8, 2021, 8:09 pm
Enzyvant receives fda approval for rethymic® (allogeneic processed thymus tissue-agdc), a one-time regenerative tissue-based therapy for pediatric congenital athymia
RETHYMIC is the first and only FDA-approved treatment indicated for immune reconstitution in pediatric patients with congenital athymia...
October 8, 2021, 8:09 pm
Enzyvant receives fda approval for rethymic® (allogeneic processed thymus tissue-agdc), a one-time regenerative tissue-based therapy for pediatric congenital athymia
RETHYMIC is the first and only FDA-approved treatment indicated for immune reconstitution in pediatric patients with congenital athymia...
October 8, 2021, 8:09 pm
Should you buy chemocentryx stock as shares spike 70% on avacopan approval?
On Friday, ChemoCentryx Inc. (NASDAQ:CCXI) shares spiked nearly 70% after announcing the Food and Drug Administration (FDA) had...
October 8, 2021, 4:30 pm